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divided by the total number of days). RESULTS: Most of the
62,754 beneﬁciaries had an index prescription of BETA, fol-
lowed by ACEi, DIU, CCB, and ARB. Persistence rates at 180
and 360 days were highest for ARB (71.0 and 52.7%, valsartan
77.1 and 59.3%), followed by CCB (51.5 and 34.4%), ACEi
(50.2 and 34.5%), DIU (41.3 and 26.0%), and BETA (25.1 and
13.6%). After adjusting for age, sex, and diabetic comorbidity,
the persistence remained signiﬁcantly higher for ARB compared
to all other drug classes. The MPR for 180 and 360 days showed
a similar pattern with the highest ratio for ARB (0.88 and 0.84;
valsartan 0.92 and 0.87), followed by CCB (0.73 and 0.66),
ACEi (0.72 and 0.67), DIU (0.70 and 0.63), and BETA (0.51 and
0.45). CONCLUSION: ARBs, and valsartan as a representative
of the class, showed the highest persistence and compliance sug-
gesting that a more sustained blood pressure control could be
expected from utilization of ARBs and Valsartan.
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Lack of compliance is a major factor responsible for the differ-
ences between clinical trial results and real effectiveness in daily
medical practice, contributing to an insufﬁcient control of the
cardiovascular risk factors (CVRF). Knowledge of the factors
contributing to lack of compliance is limited, and in Spain data
are scarce. OBJECTIVES: 1) To indirectly determine the level of
compliance among patients with hypertension and/or dyslipi-
demia; 2) To determine factors associated with compliance.
Patients and METHODS: A total of 9001 hypertensive and/or
dyslipidemic patients from four primary care centres in Catalo-
nia were enrolled in Disease Management programmes during
the previous four years. Compliance was estimated by the rela-
tionship between the amount of dispensed and prescribed pills.
1) The levels of compliance of dyslipidemic patients without
hypertension (DL-non HT), hypertensive patients with dyslipi-
demia (HT + DL) and hypertensives without dyslipidemia 
(HT-non DL) were compared. 2) An stepwise, multivariate,
descriptive; multiple regression model was designed in order to
explain compliance. RESULTS: 1) Compliance was 79% in DL-
non HT, signiﬁcantly lower than in HT + DL (81.2%, p <
0.0001) and in HT-non DL (82.4%, p < 0.0001). There were
also statistically signiﬁcant differences between these last two
groups (p = 0.0014). 2) Explanatory variables of a better com-
pliance in the multivariate analysis were a) patient related
factors: labour inactivity (p < 0.0001); b) management related
factors: speciﬁc doctor (p < 0.0001) and intensity of follow-up
(p = 0.04) and c) drug related factors: the drug group (p <
0.0001); the drug price (the more price the more compliance (p
= 0.0062) and the number of active principles used (the more
number the more compliance, p = 0.019). CONCLUSIONS: 1)
Dyslipidemic patients show a worse compliance than hyperten-
sive patients, and dyslipidemia worsened global compliance in
hypertensive patients. 2) Patient characteristics, doctor attitude,
follow-up intensity, drug group and simplicity of treatment are
related to compliance in daily medical practice.
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OBJECTIVES: To evaluate the long-term clinical and cost out-
comes of adding Niaspan® to statin treatment in patients with
persistently low HDL-c on statin monotherapy. METHODS:
Two models were developed to project long-term clinical and
economic outcomes. The ﬁrst model (second order Monte Carlo
simulation) simulated the evolution of lipid levels with treatment
and the second (Markov model) was designed to calculate the
risk of coronary heart disease (CHD) events each subsequent
year. Transition probabilities for CHD events were derived from
the Framingham risk formulae. Baseline cohort characteristics
and simvastatin treatment effects were taken from the 4S lipid
triad sub-group. Patients with persistently low HDL-c 
(<1.03mmol/L) on statin treatment received either add-on
Niaspan® 1g to 2g daily or continued statin monotherapy.
Niaspan® dosing followed maintenance dose recommendations
and treatment effects were taken from several clinical trials
(European SPC). Direct medical costs were accounted (cardio-
vascular complications and drug costs). Annual discount rates of
0% and 3.5% (Austria), 3% (Sweden and Norway) were applied
to clinical outcomes and costs. RESULTS: 68.9% of patients
were projected to have persistently low HDL-c levels after statin
treatment. In these patients mean undiscounted life expectancies
(LE) of 20.96 years and 20.46 years were projected for the
Niaspan® and statin monotherapy arms respectively. Lifetime
direct medical costs were higher by €8079 in Austria, €4723 in
Sweden and €5638 in Norway with addition of Niaspan®. Incre-
mental cost-effectiveness ratios based on discounted LE were
€16,306 (€17,635) per life year gained in Austria, €16,543
(€16,652) in Sweden and €19,748 (€21,194) in Norway for
statin plus Niaspan® 1g (and 2g) versus statin monotherapy.
CONCLUSIONS: In Austria, Sweden and Norway, raising HDL-
c with the addition of Niaspan® to statin therapy was projected
to be cost-effective compared to statin monotherapy in patients
with dyslipidemia and persistently low HDL-c.
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OBJECTIVES: To evaluate the long-term clinical and cost out-
comes of adding Niaspan® to statin treatment in patients with
persistently low HDL-c on statin monotherapy. METHODS:
Two models were developed to project long-term clinical and
economic beneﬁts of treatment. The ﬁrst simulated the evolution
of lipid levels with treatment utilising second order Monte Carlo
methodology, and the second was designed to calculate the risk
of coronary heart disease (CHD) events each subsequent year
using standard Markov modeling techniques. Transition proba-
